Ultragenyx Pharma (RARE) Misses Q2 EPS by 45c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update
August 2, 2021 4:05 PM EDTSecond quarter 2021 total revenue of $87.0 million including Crysvita1 revenue to Ultragenyx of $44.7 million
2021 Crysvita revenue in Ultragenyx territories1 guidance of $180 million to $190 million reaffirmed
Strong Dojolvi launch continues with approximately 220 patients on reimbursed commercial therapy in the United States
Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome to begin enrolling patients in Canada and the U.K.; U.S. pending protocol revisions
NOVATO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:... More
